Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) is now up 76.69% compared to a 12-month low of $2.36. We have seen the price to move -5.23% lower and get settled at $4.17 on 4/12/2019. At recent session, it appeared stuck in a range of $4.11 to $4.49. This company shares are 285.13% off its target price of $16.06 and the current market capitalization stands at $207.58M. The recent change has given its price a 7.53% lead over SMA 50 and -60.44% deficit over its 52-week high. The stock witnessed 10.03% gains, 18.13% gains and -33.91% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found MRNS’s volatility during a week at 5.76% and during a month it has been found around 6.6%.

Marinus Pharmaceuticals, Inc. (MRNS) Top Holders

Institutional investors currently hold around $151 million or 72.5% in MRNS stock. Look at its top three institutional owners: Bain Capital Life Sciences Investors, Llc owns $21.03 million in Marinus Pharmaceuticals, Inc., which represents roughly 10.13% of the company’s market cap and approximately 13.93% of the institutional ownership. Similar statistics are true for the second largest owner, Jennison Associates Llc, which owns 4,554,759 shares of the stock are valued at $18.99 million. The third largest holder is Granite Point Capital Management, L.P., which currently holds $11.09 million worth of this stock and that ownership represents nearly 5.34% of its market capitalization.

Marinus Pharmaceuticals, Inc. 13F Filings

At the end of December reporting period, 53 institutional holders increased their position in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) by some 13,789,163 shares, 49 decreased positions by 5,455,675 and 16 held positions by 16,961,502. That puts total institutional holdings at 36,206,340 shares, according to SEC filings. The stock grabbed 25 new institutional investments totaling 3,230,513 shares while 27 institutional investors sold out their entire positions totaling 3,403,222 shares.

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Insider Trades

Multiple company employees have indulged in significant insider trading. Marinus Pharmaceuticals, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that CFO Smith Edward F has sold 2,492 shares of Marinus Pharmaceuticals, Inc. (MRNS) in the trading session dated Jan. 29, 2019. These shares are worth $7,626 and were traded at $3.06 each. The SEC filing shows that Cashman Christopher Michael performed a sale of 8,142 shares. The CEO disposed these shares by way of transaction on Jan. 28, 2019. The company’s shares were given away at $3.13 per share worth to an income of some $25,484 to the account of Cashman Christopher Michael.

CFO, Smith Edward F, sold 3,000 common shares of Marinus Pharmaceuticals, Inc. (MRNS) in the open market. In a transaction dated Jan. 29, 2018, the shares were put up for sale at an average price of $7.91, raking in a sum of $23,730. After this sale, 49,800 common shares of MRNS are directly owned by the insider, with total stake valued at $207,666.

In the transaction dated Jan. 18, 2018, a great number of shares sold came courtesy the CEO; Cashman Christopher Michael disposed a total of 9,566 shares at an average price of $6.28, amounting to approximately $60,074. The insider now directly owns 247,903 shares worth $1,033,756.

Marinus Pharmaceuticals, Inc. (MRNS) Analyst Guide

Several analysts have released their opinion on Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), with 4 analysts believing it is a strong buy. Whereas 1 of them predict the stock is a hold. Also, there are 3 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.62 average brokerage recommendation [T1].